A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19

COVID-19 Vaccine Clinical Trial

Official title:

A Parallel Group, Prospective, Randomized, Two-arm, Open-label Study to Evaluate the Immunogenicity, Safety, and Tolerability of Heterologous 3rd Boost of MVC-COV1901 in Adults With 2 Doses of ChAdOx1-nCov-19 in 3 Months and 6 Months

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05097053
• Other study ID #: TYGH110044
• Status: Recruiting
• Phase: Phase 4
• Start date: October 7, 2021
• Est. completion date: July 2022

Study information

• Verified date: December 2021
• Source: Taoyuan General Hospital
• Contact: Chieh-Yu Cheng, MD.PhD.
• Phone: +886-3-3699721
• Email: s841060[@]gm.ym.edu.tw
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This primary objective of the study is to measure the anti-SARS-CoV-2 neutralizing antibody titers in adult participants in order to demonstrate the immunogenicity and safety of heterologous third-boost with MVC-COV1901, in terms of the neutralizing antibody GMTs at 28 days after the study intervention. This study also assesses the safety and tolerability of the study intervention and explores the immunogenicity by the antigen-specific immunoglobulin as well as the potential efficacy of study intervention in preventing COVID-19. This study is aimed to recruit participants at single study site in Northern Taiwan.

Description:

This a parallel group, prospective, randomized, two-arm, open-label, single-center study to be conducted in approximately 200 healthy participants aged 20 to 64 years who have had their two doses of ChAdOx1-nCov-19 (Astra Zeneca). Preparation and administration of study intervention will be performed by authorized unblinded site personnel. Eligible participants will receive MVC-COV1901 vaccine after a 3-month (Group A: < 16 weeks and ≥ 12 weeks) or 6-month (Group B: < 28 weeks and ≥ 24 weeks) interval apart from their second dose of ChAdOx1-nCov-19.

The study consists of 6 on-site visits:

• Day -28 to Day 1, Visit 1 (Screening)

• Day 1, Visit 2 (study intervention) : randomization Group A and B

Group A:

• Day 1, Visit 2: treatment

• Day 29 ± 3 days, Visit 3

• Day 85 ± 3 days, Visit 4

• Day 169 ± 3 days, Visit 5

Group B:

• Day 1, Visit 2

• Day 85 ± 3 days, Visit 3: treatment

• Day 113 ± 3 days, Visit 4

• Day 169 ± 3 days, Visit 5

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: July 2022
• Est. primary completion date: March 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 64 Years

Eligibility

Inclusion Criteria:

1. Male or female participant aged 20 to 64 years at randomization.

2. Has received two doses of the ChAdOx1-nCov-19 (Astra-Zeneca) 12 to 16 weeks before randomization.

3. Female participant must:

1. Be either of non-childbearing potential, i.e. surgically sterilized (defined as having undergone hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year post-menopausal;

2. Or, if of childbearing potential, be abstinent or agree to use medically effective contraception from 14 days before screening to 30 days following the last administration of study intervention. Acceptable forms include:

i.Implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine system ii.Established use of hormonal methods (injectable, pill, patch or ring) combined with barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository c.Have a negative pregnancy test

4. Participant is willing and able to comply with all required study visits and follow-up required by this protocol.

5. Participant or the participant's legal representative must understand the procedures of the study and provide written informed consent.

Exclusion Criteria:

1. Pregnant or breast feeding or have plan to become pregnant within 30 days after the last administration of study intervention.

2. Currently receiving or received any investigational intervention within 30 days prior to the first dose of study intervention.

3. Administered any licensed live-attenuated vaccines within 28 days or other licensed non-live-attenuated vaccines within 7 days prior to the first dose of study intervention.

4. Administered any blood product or intravenous immunoglobulin administration within 12 weeks prior to the first dose of study intervention.

5. Currently receiving or anticipate to receive concomitant immunosuppressive or immune-modifying therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or < 2 weeks of daily receipt of prednisone less than 20 mg or equivalent) within 12 weeks prior to the first dose of study intervention.

6. Currently receiving or anticipate to receive treatment with tumor necrosis factor (TNF)-a inhibitors, e.g. infliximab, adalimumab, etanercept within 12 weeks prior to the first dose of study intervention.

7. Major surgery or any radiation therapy within 12 weeks prior to the first dose of study intervention.

8. Has received any other investigational or licensed COVID-19 vaccine.

9. Immunosuppressive illness or immunodeficient state, including hematologic malignancy, history of solid organ, bone marrow transplantation, or asplenia.

10. A history of malignancy with potential risk for recurrence after curative treatment, or current diagnosis of or treatment for cancer (exceptions are squamous and basal cell carcinomas of the skin and treated uterine cervical carcinoma in situ, at the discretion of the investigator).

11. Bleeding disorder considered a contraindication to IM injection or phlebotomy.

12. Known SARS-CoV-2 infection in the recent 3 months prior to the first dose of study intervention.

13. A history of cerebral venous sinus thrombosis, heparin-induced thrombocytopenia or antiphospholipid syndrome.

14. Participant who, in the investigator's judgement, is not in a stable condition and by participating in the study could adversely affect the safety of the participant, interfere with adherence to study requirements or evaluation of any study endpoint. This may include a participant with ongoing acute diseases, severe infections, autoimmune disease, laboratory abnormality or serious medical conditions in the following systems: cardiovascular, pulmonary, hepatic, neurologic, metabolic, renal, or psychiatric.

15. A history of hypersensitivity to any vaccine or a history of allergic disease or reactions likely to be exacerbated by any component of the MVC-COV1901.

16. Body (oral, rectal, or ear) temperature = 38.0°C or acute illness (not including minor illnesses such as diarrhea or mild upper respiratory tract infection at the discretion of the investigator) within 2 days before the first dose of study intervention.

Related Conditions & MeSH terms

• COVID-19
• COVID-19 Vaccine

Intervention

Biological:
• MVC-COV1901(3 Months)
MVC-COV1901 vaccine after a 3-month Interval
• MVC-COV1901(6 Months)
MVC-COV1901 vaccine after a 6-month Interval

Locations

Country	Name	City	State
Taiwan	Taoyuan General Hospital	Taoyuan

Sponsors (2)

Lead Sponsor	Collaborator
Taoyuan General Hospital	Medigen Vaccine Biologics Corp.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Exploratory Efficacy	To estimate the efficacy of heterologous third-boost (MVC COV1901), in the prevention of COVID-19; Number of laboratory-confirmed COVID-19 cases occurring = 7 days after study intervention.; Number of laboratory-confirmed COVID-19 severe cases occurring = 7 days after study intervention.	Day 1 to Day 169
Primary	Primary Immunogenicity	To evaluate the immunogenicity of heterologous third-boost (MVC-COV1901) in 3 months, compared to 6 months, in terms of neutralizing antibody; Geometric Mean Titers (GMT)	Day1 to 28 days after vaccination
Primary	Primary Safety	To evaluate the safety and tolerability of heterologous third-boost (MVC-COV1901) from Day 1 to 28 days after the study intervention; The number and percentage of participants with the occurrence of: Solicited local adverse events (AEs); Solicited systemic AEs; Unsolicited AEs	Day1 to 28 days after vaccination
Secondary	Secondary Immunogenicity	To evaluate the immunogenicity of heterologous third-boost (MVC-COV1901) in terms of antigen-specific immunoglobulin titers; GMT	Day 1 and Day 169
Secondary	Secondary Safety	To evaluate the safety of heterologous third-boost (MVC-COV1901), over the study period; The number and percentage of participants with the occurrence of: MAAEs; AESIs; VAED; SAEs	Day 1 to Day169